Insider Selling: Ventyx Biosciences (NASDAQ:VTYX) CEO Sells 47,345 Shares of Stock

Ventyx Biosciences, Inc. (NASDAQ:VTYX) CEO Raju Mohan sold 47,345 shares of the business’s stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $7.72, for a total transaction of $365,503.40. Following the completion of the sale, the chief executive officer directly owned 2,372,863 shares of the company’s stock, valued at $18,318,502.36. This represents a 1.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ventyx Biosciences Trading Up 12.9%

Shares of NASDAQ:VTYX traded up $1.00 on Friday, reaching $8.74. 2,836,325 shares of the company traded hands, compared to its average volume of 2,101,134. The stock has a market capitalization of $623.69 million, a P/E ratio of -5.83 and a beta of 1.22. The business’s 50-day simple moving average is $7.79 and its 200 day simple moving average is $4.44. Ventyx Biosciences, Inc. has a 52 week low of $0.78 and a 52 week high of $10.55.

Ventyx Biosciences (NASDAQ:VTYX) last issued its earnings results on Thursday, November 6th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.13. Sell-side analysts expect that Ventyx Biosciences, Inc. will post -2.09 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on VTYX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ventyx Biosciences in a research note on Wednesday, October 8th. Oppenheimer boosted their price objective on shares of Ventyx Biosciences from $9.00 to $14.00 and gave the company an “outperform” rating in a research report on Monday, October 27th. Wells Fargo & Company upped their price objective on shares of Ventyx Biosciences from $11.00 to $14.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. HC Wainwright raised Ventyx Biosciences from a “neutral” rating to a “buy” rating and set a $18.00 target price on the stock in a research note on Wednesday, November 5th. Finally, Canaccord Genuity Group boosted their price target on Ventyx Biosciences from $14.00 to $16.00 and gave the company a “buy” rating in a report on Friday, November 7th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Ventyx Biosciences presently has an average rating of “Moderate Buy” and a consensus target price of $15.50.

Institutional Trading of Ventyx Biosciences

Large investors have recently bought and sold shares of the company. Hudson Bay Capital Management LP bought a new position in shares of Ventyx Biosciences in the 2nd quarter worth approximately $34,000. Pallas Capital Advisors LLC bought a new stake in shares of Ventyx Biosciences during the second quarter valued at approximately $38,000. Engineers Gate Manager LP purchased a new stake in Ventyx Biosciences in the second quarter worth $42,000. Persistent Asset Partners Ltd bought a new position in Ventyx Biosciences in the third quarter worth $51,000. Finally, Jump Financial LLC purchased a new position in Ventyx Biosciences during the second quarter valued at $53,000. 97.88% of the stock is owned by institutional investors.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.